🎉 M&A multiples are live!
Check it out!

Public Comps and Valuation Multiples
for BioTech

Benchmark revenue and EBITDA valuation multiples for public comps like Danaher, Johnson & Johnson, Vertex Pharmaceuticals, Novo Nordisk and Gilead Sciences.

BioTech

See analyst estimates and all valuation multiples for BioTech
Company EV EV/LTM Revenue EV/LTM EBITDA
$753B 14.2x 35.2x
$403B 6.9x 15.2x
$391B 4.3x 11.9x
$323B 6.6x 13.1x
$156B 5.4x 12.2x
$156B 6.5x 20.5x
$136B 2.9x 10.8x
$134B 2.5x 8.5x
$117B 10.1x 35.5x
$97.6B 2.3x 6.6x
$87.0B 5.5x 16.7x
$74.3B 7.9x 18.4x
$70.1B 1.3x 6.1x
$10.2B 2.9x 8.2x
$8.2B 10.7x 39.8x
$7.4B 9.3x n/a
$7.2B n/a n/a
$6.9B 7.4x 26.6x
$6.0B 13.4x 42.3x
$4.5B 218.9x -7.5x
$3.2B 81.9x -7.1x
$3.0B 3.0x 19.5x
$2.8B 3.7x 5.4x
$2.0B 2.1x 7.1x
$1.9B 569.6x -4.8x
$1.9B 1.6x 5.0x
$1.8B n/a n/a
$1.7B 2.5x 4.0x
$1.4B n/a -6.4x
$1.4B 109.4x -2.8x
$1.3B 1.1x 3.1x
$1.3B n/a -8.1x
$1.1B 1.8x 5.8x
$1.0B n/a n/a
$1.0B n/a -2.9x
$1.0B 4.0x 5.1x
$914M 3.0x 27.3x
$914M 2.6x 30.7x
$768M 7.0x n/a
$756M 2.3x 16.5x
$728M 26.4x -3.2x
$717M 1.0x 4.0x
$607M n/a -1.6x
$604M 1.3x 6.1x
$592M 1.7x 10.1x
$586M n/a n/a
$519M 26.9x -2.8x
$453M 2.5x n/a
$382M 78.0x n/a
$355M 1.4x n/a
$332M 1.2x 7.2x
$314M 1.0x 8.3x
$305M 2.6x 20.4x
$298M 2.0x -2.7x
$298M 736.7x n/a
$254M 4.1x -5.5x
$243M 18.0x n/a
$241M n/a -7.6x
$232M 1.6x -1.2x
$214M 28.2x -2.3x
$214M n/a n/a
$196M 363.7x n/a
$194M 16.2x -2.6x
$185M 71.5x -10.0x
$173M 8.7x n/a
$140M n/a n/a
$136M n/a -4.0x
$123M n/a n/a
$114M n/a n/a
$111M 83.3x -12.9x
$106M 0.9x 27.5x
$52.5M 6.1x n/a
$48.4M 8.7x -4.3x
$33.0M 2.0x n/a
$27.9M 1.4x n/a
$24.4M n/a -7.3x
$20.6M 33.9x n/a
$16.4M n/a -0.6x
$13.4M 0.8x n/a
$13.2M 2.2x n/a
$12.9M n/a n/a
$11.1M 7.0x n/a
$4.9M 0.5x n/a
-$0.5M n/a n/a
-$4.7M -0.4x n/a
-$11.8M -7.9x 0.2x
-$16.8M n/a n/a
-$23.5M n/a n/a
-$24.1M -2.5x 0.2x
-$27.6M -30.9x n/a
-$31.9M n/a n/a
-$74.9M n/a n/a
-$88.2M -32.9x 1.4x
-$94.7M -40.7x 0.4x

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.